Improvement or Worsening of Disease Activity After Switch to Sarilumab in Patients With Rheumatoid Arthritis With a Partial Response to Adalimumab.

Jeffrey R Curtis,Daniel Aletaha,Gerd Burmester,Kerri Ford,Hubert van Hoogstraten,Amy Praestgaard,Vivian P Bykerk

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases（2023）

引用 0|浏览11

暂无评分

摘要

Partial responders to adalimumab who switched to sarilumab had a low likelihood of experiencing meaningful worsening, with most patients showing meaningful improvement or no change in disease activity. This may help alleviate patients' fears of worsening when considering switching to a treatment with a different mechanism of action.

查看译文

关键词

rheumatoid arthritis, CDAI, adalimumab, sarilumab, swollen joint count

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要